NCT06848920View on ClinicalTrials.gov

Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Differentiated Thyroid Carcinoma (DTC)Neoadjuvant Therapy
Interventions
DRUG

Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment

Sinibolimab combined with Lenvatinib in neoadjuvant treatment

Trial Locations (1)

310003

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER